Summary.-The HT29R human colonic adenocarcinoma cell line grows as locally invasive, mucin-secreting tumours in immunosuppressed mice with a doubling time of 6 days. These tumours may be disaggregated to give single-cell suspensions with plating efficiencies of 25-45% in technically simple itn vivo-in vitro cell-survival assays. The effect of maximum tolerated doses of 5 -fluorouracil, melphalan and cyclophosphamide on in situ growth is only slight. In vivo-in vitro cell-survival assays are consistent with these in situ results.
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The relative ease of experimental manipulation and the high clonogenic efficiency of this tumour make it a useful addition to human tumour xenograft models.
IN VIVO-IN VITRO CLONOGENIC ASSAYS
provide an important method of estimating the response of human tumour xenografts to chemotherapy. Methods of measuring the clonogenic ability of cells obtained from disaggregated heterotransplanted tumours have been described, in which the tumour cells form colonies in agar either in vitro (Courtenay & Mills, 1978) or in diffusion chambers implanted i.p. into mice (Smith et al., 1976) . Such methods, however, are relatively complex to perform and have been generally reported as giving low plating efficiencies (PE). This may truly reflect the small proportions of potentially clonogenic cells in in vivo tumours. Conversely, these low PEs may be due to technical problems in the assay, which only allow a proportion of the clonogenic cells to divide effectively.
The HT29R human colonic adenocarcinoma cell line has already been investigated for its in situ response to a number of cytotoxic agents (Warenius et al., 1980 (Warenius et al., , 1981 . This human tumour cell line might provide a model which could be experimentaly manipulated with an ease which was closer to that of animal-tumour models, but the biological characteristics and drug responses of which were similar to that of heterotransplanted human tumours primarily established as xenografts. We have thus attempted to define the optimal conditions of this tumour in in vivo-in vitro clonogenic assays and compare these results to those of in situ assays.
METHODS
HT29R is a once-recloned variant of the HT29 cell line (Von Kleist et al., 1975 Drugs.-((2-(di(2-chloroethyl)amino-1 -oxa-3-aza-2-phosphacyclohexane)) Endoxana, W. B. Pharmaceuticals, CY) was dissolved in phosphate-buffered saline (PBS). Melphalan ((N,N-p-di-2-chlorethylaminophenylalanine); Alkeran Injection, Wellcome) was dissolved in 10% acidified ethanol/propylene glycol-K2HPO4 buffer. 5-Fluorouracil ((5-fluoropyrimidine 2,4-(1H,3H)-dione), Roche Products, FU) was dissolved in PBS. Drug solutions were prepared immediately before use and injected i.p. in a volume of 0-01 ml/g body wt. Controls received vehicle alone.
Drugs were tested at maximum tolerated dose (no more deaths than in control group and < 15% weight loss) and at lower doses.
Animals.-Male CBA mice were obtained from O.L.A.C. 1976 (Shaws Farm, Blackthorne, Bicester). They were immunosuppressed by a modification of the method of Kopper & Steel (1975) as previously described (Warenius et al., 1980) . Mice were thymectomized at 4 weeks of age and given 9-2 Gy whole-body irradiation from a 60Co unit 2 weeks later. These animals were reconstituted within 12 h by 2x 105 syngeneic nucleated marrow cells.
In vivo tumours. -Tumours were initiated by s.c. inoculation of 106 HT29R in vitro cells 24 h after 9-2 Gy total-body irradiation and marrow reconstitution. Cytotoxic drug treatment was started 21-23 days later, when the mean tumour volume was 120-150 mm3 (range 80-250 mm3). In order to provide as much homogeneity as possible in control and treated groups stratification into subgroups by volume was carried out and equal proportions of these subgroups were randomized between the various experimental groups.
Tumours were measured in 2 directions at right angles by calipers, and their volumes calculated from the formula 7r/6(d) 3. The validity of this method was tested in an initial series of animals by comparing volumes determined by caliper measurement with those determined by volume displacement on tumours after excision. This showed good agreement for tumours with volumes between 50 and 800 mm3.
Disaggregation of in vivo tumours.-A number of disaggregation mixtures were compared:
A-Trypsin 0.5% w/v, +versene 0.025% w/v, + DNase 0-2 mg/ml.
B-Pronase 15 mg/ml, +collagenase 10 mg/ml, +versene 0 025% w/v, +DNase 0-2 mg/ml. C-Collagenase 10 mg/ml, + versene 0.025% w/v, + DNase 0-2 mg/ml. D-Pronase 15 mg/ml, + versene 0025% w/v, +DNase 0-2 mg/ml. All tumours were chopped finely under sterile condition in just sufficient PBS to keep the tissue moist. Equal volumes of tumour brei were then mixed with 5 ml of the relevant disaggregating solution and stirred at room temperature for from 30-180 min. The disaggregated cell suspension was then filtered through a sterile gauze and a singlecell suspension obtained by aspiration 2-3 times through a 23-gauge needle.
Clonogenic assays.-Optimal conditions for colony-forming assays were defined with regard to culture-medium composition, FCS concentration and time at which colonies were assessed. Disaggregated single-cell suspensions were counted and adjusted to multiples of 100 cells/ml. The cell-survival curve for 5-fluorouracil FU (C) is different, having an initial drop but subsequently flattening out. As with CY and melphalan, doses of FU of the order of the LD50/30 (220 mg/kg) have only a small effect on PE.
Effect of chemotherapy on in vivo tumours
The effects of the drugs CY, FU and melphalan on the in situ growth of HT29R are shown in Fig. 4 . The maximum tolerated dose of FU as a single i.p. injection or 5 daily injections was 146 mg/kg. Both the single FU injection and the 5 daily injections produced a significant inhibition of tumour growth at 12 days. This inhibition was not marked, however, and by Day 18 the difference between treated and control groups was already much smaller. Tumour measurements were discontinued in most experiments after Day 18 because of the high percentage of ulceration. The drugs CY, (C) and melphalan (D) produced less inhibition of growth of the HT29R tumour than did FU. For melphalan, it was not possible, with the size of the experiment used, to demonstrate any statistically significant inhibition of growth.
DISCUSSION
A disadvantage of the small response of HT29R to maximum tolerated doses of cytotoxic drugs in vivo is that it is impossible to perform in situ growth delay experiments without using very large numbers of animals in each treatment group. Also, when drugs only give slight inhibition of in vivo tumour growth, it is not practicable to produce dose-response curves.
These facts, coupled with the other problems of in situ growth-delay assays in heterotransplanted tumours, such as residual host immunity, make the use of in vivo-in vitro cell-survival assays particularly appealing.
In vivo-in vitro clonogenic assays with high PE can be performed on HT29R (Smith et al., 1976; Courtenay & Mills, 1978) . However, the latter were performed on xenografts derived as primary heterotransplants from human tumours, whereas HT29R has been established as an in vitro cell line for > 100 passages.
A great degree of selection is likely to occur when we attempt to perpetuate individual human tumours as replicable model systems under experimental conditions. Thus, how closely the behaviour of any human tumour model system reflects that of the primary from which it is derived must be uncertain. Also, as has been pointed out by Steel & Peckham (1980) , individual differences in the response of xenografts to chemotherapy make it unlikely that anv one xenograft tumour can be a representative model. Although HT29R is an established in vitro cell line, it is capable of growth as p)oorly differentiated mucin-secreting adenocarcinomas which invade locally. The mean volume-doubling time of these tumours (6 days) is comparable to that of some established colonic adenocarcinoma heterotransplants such as HX 13 and HX18 (Kopper & Steel, 1975) .
In this paper we have shown that HT29R responds poorly to FU (one of the most useful agents clinically against colon cancer) and also to the 2 alkylating agents melphalan and CY. The in 8itu response to methyl CCNU (not shown) was similar to that for melphalan.
The in vivo-in vitro cell-survival doseresponse curves with the 2 bifunctional alkylating agents CY and melphalan are characterized by large shoulders extending to LD50/30 doses for each of the drugs in question.
Because only small differences can be shown in in vivo-in vitro cell survival wlth doses of drug which are less than the LD50/30, and because there is only slight growth inhibition in in situ growth assays with doses below the MTD, it is not possible to correlate the 2 assays nuimerically. However, the in vivo-in vitro cell-survival assay is consistent, with the in situ growth-delay assays, in that both show very little response to the MTD of the relevant cytotoxic agents. The cell-survival curve for FU contrasts with that for the alkylating agents, in that it flattens out with increasing doses. This appearance is consistent with FU behaving as a phase-specific agent under these conditions. HT29R would thus appear to provide a useful human tumour xenograft model with a poor response to chemotherapy and a technically simple in vivo-in vitro clonogenic assay system with high plating efficiency.
